BioSpace News Archive

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab

To Date, More Than $600 Million Committed Through Personal Protective Equipment Reimbursements, Customer Premium Relief, Provider Loans and Other Financial Assistance Initiatives to Support Providers, Members, Employees and Communities

Anivive Lifesciences, a biotechnology company focused on developing first-in-class therapies, today announced the initiation of two pre-clinical studies to further evaluate the in vivo efficacy and safety of GC376 as a treatment for COVID-19.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

Teladoc Health, Inc. announced that it has completed its acquisition of Santa Barbara, Calif.-area based InTouch Health.

Reference is made to the minutes from Nordic Nanovector ASA’s annual general meeting held on 10 June 2020 in Oslo, Norway.

CARAG AG, a privately-held Swiss medical device development company, announced receiving U.S. Food and Drug Administration Investigational Device Exemption approval for its Carag Bioresorbable Septal Occluder.

BioArctic AB to publish the company’s Interim Report for the period January - June 2020 on Friday, July 1, 2020, at 08:00 a.m. CET.

BioInvent International AB announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. until the end of 2020.

AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board.